-
Prospect of new drug research and development: the era of heavy bomb will continue
Time of Update: 2020-04-03
Many well-known analysts in the pharmaceutical industry have assessed the current status of drug development, indicating that the dawn of new drug research and development has emerged Human genomics p
-
Huangtengsu glucose injection, a class 2 new drug of Anhui Shuanghe Pharmaceutical Co., Ltd., took 9 years to obtain the production approval
Time of Update: 2020-04-03
Anhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China Resources Shuanghe Pharmaceutical Co., Ltd., has applied for the production of Huangtengsu glucose injection (acceptance No.
-
Production approval of 6 kinds of cefmetazole sodium APIs for Fuan pharmaceutical industry
Time of Update: 2020-04-03
Fuan Pharmaceutical Co., Ltd announced in the evening of the 26th that the company's six kinds of chemical drugs "Cefmetazole sodium" APIs have recently been received from the State Food and Drug Admi
-
Four projects in Guizhou Province are supported by the fourth batch of subprojects in the 12th Five Year Plan of the major national science and technology project of "major new drug creation"
Time of Update: 2020-04-03
Recently, four projects in Guizhou Province have been supported by the fourth batch of subprojects of the 12th Five Year Plan, a major science and technology project of "major new drug creation", with
-
7-year review long run after the approved production of Zhifei biological AC Hib triple vaccine
Time of Update: 2020-04-03
The AC Hib triple vaccine independently developed by Beijing green bamboo, a wholly-owned subsidiary of Zhifei biology, was finally approved for production after a seven-year review run It is reported
-
Tonghua Dongbao's six clinical trials of new drugs have been withdrawn by the enterprise
Time of Update: 2020-04-03
On January 31, Xinbang Pharmaceutical (002390) was sealed on the drop board all day On the evening of January 30, Xinbang pharmaceutical announced that the company will conduct a series of additional
-
Clinical application of the first McAb for class 2 biological products in Shanghai medicine
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on May 14, the "recombinant anti-CD20 humanized monoclonal antibody injection" for class 2 biological products declared by Sha
-
Hengrui medicine enters the outbreak period of new drugs and generic drugs
Time of Update: 2020-04-03
Hengrui pharmaceutical has declared 75 generic drugs in the past four years, and will enter the mass listing period of heavy-duty generic drugs in the future Through the layout of the field of drugs f
-
CFDA approved the world's first Sabin polio vaccine
Time of Update: 2020-04-03
On January 14, 2015, the State Food and Drug Administration approved the production registration application of the world's first Sabin vaccine (single vaccine) The vaccine is developed by the Institu
-
Jichuan Pharmaceutical Co., Ltd. approved production of prulifloxacin
Time of Update: 2020-04-03
According to the information of the State Food and Drug Administration (CFDA), the evaluation status of pulifloxacin dispersible tablets, a generic drug of Jichuan Pharmaceutical Co., Ltd., has change
-
Haizheng pharmaceutical "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection" obtained clinical approval
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the approval status of "recombinant human mouse chimeric anti-CD20 monoclonal antibody injection", a clinical heavyweight McA
-
The clinical application for class 1.1 new drugs led by Shenyang Pharmaceutical University was accepted
Time of Update: 2020-04-03
Recently, new progress has been made in the development of major new drugs in Liaoning Province The application for clinical research registration of cytarabine hydrochloride valine ester and its tabl
-
All human monoclonal antibody injection of Watson biological recombinant anti TNF - α obtained the approval of clinical trial in Korea
Time of Update: 2020-04-03
Jiahe biopharmaceutical Co., Ltd., a subsidiary of Watson biology, has obtained the clinical trial approval document issued by the Ministry of food and drug safety of South Korea for its independently
-
Zhongzhu holding's acquisition of xintaidayi in a new anticancer drug recombinant human endostatin adenovirus injection
Time of Update: 2020-04-03
Zhongzhu holding, which has been suspended for three weeks, announced on the evening of January 23 that it intends to acquire 70% of the equity of Guangzhou new TEDA Biotechnology Co., Ltd., as well a
-
The project of "industrialization of new anesthetic drugs hydromorphone hydrochloride and alfentanil" of humanwell pharmaceutical has obtained the state subsidy of 50 million yuan
Time of Update: 2020-04-03
Humanwell announced in the evening of April 2 that four ministries and commissions of the state planned to arrange a state subsidy of 50 million yuan for the company's "industrialization of new narcot
-
Daqing Huake transferred 15 million new drug technology of wuhudan capsule to Yangzijiang pharmaceutical
Time of Update: 2020-04-03
Daqing Huake Co., Ltd announced in the evening of March 22 that the company signed the "new drug technology transfer contract" with Beijing Haiyan Pharmaceutical Co., Ltd of Yangtze River Pharmaceutic
-
AstraZeneca cooperates with the medical department of Shenzhen University to develop drugs for chronic kidney disease
Time of Update: 2020-04-03
AstraZeneca announced on March 27 that it had reached a cooperation agreement with the medical department of Shenzhen University to jointly carry out the preclinical development of chronic kidney dise
-
Wuhan Guanggu humanwell class 1.1 analgesic meisuoshuli obtained clinical approval
Time of Update: 2020-04-03
Humanwell pharmaceutical announced in the evening of June 23 that the company's joint-stock subsidiary, Wuhan Optics Valley humanwell, had obtained the clinical approval documents for the 1.1-class ch
-
Baiji Shenzhou cooperates with Merck xuelanuo to develop new anticancer drugs
Time of Update: 2020-04-03
Merck has signed an agreement with Beijing based biotech company beigene to jointly develop an experimental cancer drug This latest sign shows that China's fledgling life science field is developing r
-
Toluene sulfonamide injection (PTS), a new anticancer drug of HongRi pharmaceutical, has entered the green channel
Time of Update: 2020-04-03
On August 19, sun Changhai, general manager of HongRi Pharmaceutical Co., Ltd (300026 SZ), said in the investigation of the institution that the company's first class new anti-cancer drug, toluene sul
